Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    European urology. 2015 Feb 13. pii: S0302-2838(14)01250-0. doi: 10.1016/j.eururo.2014.11.055
    Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1-pT3a localized renal cell carcinoma in a comprehensive multicenter study of the CORONA project. Can we improve prognostic discrimination for patients with stage pT3a tumors?
    Brookman-May SD1,  May M2,  Wolff I3,  Zigeuner R4,  Hutterer GC5,  Cindolo L6,  Schips L7,  De Cobelli O8,  Rocco B9,  De Nunzio C10,  Tubaro A11,  Coman I12,  Truss M13,  Dalpiaz O14,  Feciche B15,  Figenshau RS16,  Madison K17,  Sánchez-Chapado M18,  Santiago Martin Mdel C19,  Salzano L20,  Lotrecchiano G21,  Zastrow S22,  Wirth M23,  Sountoulides P24,  Shariat S25,  Waidelich R26,  Stief C27,  Gunia S28
    Author information
    1Department of Urology, Ludwig Maximilians University, Munich, Germany; Janssen Pharma Research and Development, Beerse, Belgium. Electronic address: sabine.brookman-may@email.de.
    2Department of Urology, St. Elisabeth Hospital Straubing, Straubing, Germany.
    3Department of Urology, Carl Thiem Klinikum, Cottbus, Germany.
    4Department of Urology, Medical University of Graz, Graz, Austria.
    5Department of Urology, Medical University of Graz, Graz, Austria.
    6Department of Urology, Pio Da Pietrelcina Hospital, Vasto, Italy.
    7Department of Urology, Pio Da Pietrelcina Hospital, Vasto, Italy.
    8Division of Urology, European Institute of Oncology, Milan, Italy.
    9Department of Urology, Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.
    10Department of Urology, Faculty of Health Sciences, University La Sapienza, Rome, Italy.
    11Department of Urology, Faculty of Health Sciences, University La Sapienza, Rome, Italy.
    12Department of Urology, Clinical Municipal Hospital, Cluj-Napoca, Romania.
    13Department of Urology, Klinikum Dortmund, Dortmund, Germany.
    14Department of Urology, Carl Thiem Klinikum, Cottbus, Germany; Department of Urology, Klinikum Dortmund, Dortmund, Germany.
    15Department of Urology, Emergency Hospital Satu Mare, Satu Mare, Romania.
    16Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
    17Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
    18Department of Urology, Hospital Universitario Principe de Asturias, Madrid, Spain.
    19Department of Urology, Hospital Universitario Principe de Asturias, Madrid, Spain.
    20Department of Urology, G. Rummo Hospital, Benevento, Italy.
    21Department of Urology, G. Rummo Hospital, Benevento, Italy.
    22Department of Urology, Carl Gustav Carus University, Dresden, Germany.
    23Department of Urology, Carl Gustav Carus University, Dresden, Germany.
    24Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
    25Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
    26Department of Urology, Ludwig Maximilians University, Munich, Germany; Janssen Pharma Research and Development, Beerse, Belgium.
    27Department of Urology, Ludwig Maximilians University, Munich, Germany; Janssen Pharma Research and Development, Beerse, Belgium.
    28Department of Pathology, Johanniter Hospital Stendal, Stendal, Germany.
    Abstract

    BACKGROUND: The current TNM system for renal cell carcinoma (RCC) merges perirenal fat invasion (PFI) and renal vein invasion (RVI) as stage pT3a despite limited evidence concerning their prognostic equivalence. In addition, the prognostic value of PFI compared to pT1-pT2 tumors remains controversial.

    OBJECTIVE: To analyze the prognostic significance of PFI, RVI, and tumor size in pT1-pT3a RCC.

    DESIGN, SETTING, AND PARTICIPANTS: Data for 7384 pT1a-pT3a RCC patients were pooled from 12 centers. Patients were grouped according to stages and PFI/RVI presence as follows: pT1-2N0M0 (n=6137; 83.1%), pT3aN0M0 + PFI (n=1036; 14%), and pT3aN0M0 (RVI ± PFI; n=211; 2.9%).

    INTERVENTION: Radical nephrectomy or nephron-sparing surgery (NSS) (1992-2010).

    OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cancer-specific survival was estimated using the Kaplan-Meier method. Univariate and multivariate Cox proportional-hazards regression models, as well as sensitivity and discrimination analyses, were used to evaluate the impact of clinicopathologic parameters on cancer-specific mortality (CSM).

    RESULTS AND LIMITATIONS: Compared to stage pT1-2, patients with stage pT3a RCC were significantly more often male (59.4% vs 53.1%) and older (64.9 vs 62.1 yr), more often had clear cell RCC (85.2% vs 77.7%), Fuhrman grade 3-4 (29.4% vs 13.4%), and tumor size >7 cm (39.1% vs 13%), and underwent NSS less often (7.5% vs 36.6%; all p<0.001). According to multivariate analysis, CSM was significantly higher for the PFI and RVI ± PFI groups compared to pT1-2 patients (hazard ratio [HR] 1.94 and 2.12, respectively; p<0.001), whereas patients with PFI only and RVI ± PFI did not differ (HR 1.17; p=0.316). Tumor size instead enhanced CSM by 7% per cm in stage pT3a (HR 1.07; p<0.001) with a 7 cm cutoff yielding the highest prediction accuracy.

    CONCLUSIONS: Since the prognostic impact of PFI and RVI on CSM seems to be comparable, merging both as stage pT3a RCC might be justified. Enhanced prognostic discrimination of stage pT3a RCC appears to be possible by applying a tumor size cutoff of 7 cm within an alternative staging system.

    PATIENT SUMMARY: Prognosis prediction for patients with localized renal cell carcinoma up to stage pT3a can be enhanced by including tumor size with a cutoff of 7 cm as an additional parameter in the TNM classification system.


    Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.

    KEYWORDS: Cancer-specific survival, Perirenal fat invasion, Renal cell carcinoma, Renal vein invasion, Tumor size

    Publikations ID: 25684695
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt